Literature DB >> 2404904

Significance and therapeutic implications of tumor regression following radiotherapy in patients treated for squamous cell carcinoma of the oropharynx and pharyngolarynx.

J P Bataini1, C Jaulerry, F Brunin, D Ponvert, N A Ghossein.   

Abstract

The prognostic significance of tumor regression following radiotherapy was evaluated in 1,897 patients with oro- and pharyngolaryngeal cancer. Complete tumor regression occurred in 62% and 80% at the end of treatment and 2 months later, respectively. Complete regression was significantly higher for early tumors than for advanced stages and for exophytic lesions compared to deeply infiltrative cancers. Depending on tumor location, 75% to 90% of T1, T2 stages and 50% to 80% of more advanced tumors were locally controlled in patients who experienced complete tumor regression at 2 months. The local failure rate was at least 80% for those who did not have complete regression. The local failure rate for the incomplete responder was the same for early and advanced tumors. Complete tumor clearance following radiotherapy is a reliable indicator of permanent local control. Tumor regression after a dose of 5,000 to 5,500 cGy should be used as a guide to select patients who could be treated by either radical irradiation or surgery.

Entities:  

Mesh:

Year:  1990        PMID: 2404904     DOI: 10.1002/hed.2880120106

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  5 in total

Review 1.  Adaptive radiation therapy in head and neck cancer for clinical practice: state of the art and practical challenges.

Authors:  Ovidiu Veresezan; Idriss Troussier; Alexis Lacout; Sarah Kreps; Sophie Maillard; Aude Toulemonde; Pierre-Yves Marcy; Florence Huguet; Juliette Thariat
Journal:  Jpn J Radiol       Date:  2016-12-01       Impact factor: 2.374

2.  Longitudinal characterization of the tumoral microbiome during radiotherapy in HPV-associated oropharynx cancer.

Authors:  Houda Bahig; Clifton D Fuller; Aparna Mitra; Kyoko Yoshida-Court; Travis Solley; Sweet Ping Ng; Ibrahim Abu-Gheida; Baher Elgohari; Andrea Delgado; David I Rosenthal; Adam S Garden; Steven J Frank; Jay P Reddy; Lauren Colbert; Ann Klopp
Journal:  Clin Transl Radiat Oncol       Date:  2020-11-18

3.  Primary tumor regression speed after radiotherapy and its prognostic significance in nasopharyngeal carcinoma: a retrospective study.

Authors:  Ning Zhang; Shao-Bo Liang; Yan-Ming Deng; Rui-Liang Lu; Hai-Yang Chen; Hai Zhao; Zhi-Qian Lv; Shao-Qiang Liang; Lin Yang; Dong-Sheng Liu; Yong Chen
Journal:  BMC Cancer       Date:  2014-02-27       Impact factor: 4.430

4.  Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial.

Authors:  Houda Bahig; Ying Yuan; Abdallah S R Mohamed; Kristy K Brock; Sweet Ping Ng; Jihong Wang; Yao Ding; Kate Hutcheson; Molly McCulloch; Peter A Balter; Stephen Y Lai; Abrahim Al-Mamgani; Jan-Jakob Sonke; Uulke A van der Heide; Christopher Nutting; X Allen Li; Jared Robbins; Mussadiq Awan; Irene Karam; Katherine Newbold; Kevin Harrington; Uwe Oelfke; Shreerang Bhide; Marielle E P Philippens; Chris H J Terhaard; Andrew J McPartlin; Pierre Blanchard; Adam S Garden; David I Rosenthal; Gary B Gunn; Jack Phan; Guillaume Cazoulat; Michalis Aristophanous; Kelli K McSpadden; John A Garcia; Cornelis A T van den Berg; Cornelis P J Raaijmakers; Linda Kerkmeijer; Patricia Doornaert; Sanne Blinde; Steven J Frank; Clifton D Fuller
Journal:  Clin Transl Radiat Oncol       Date:  2018-08-24

5.  Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma.

Authors:  Alexandre Arthur Jacinto; Eronides Salustiano Batalha Filho; Luciano de Souza Viana; Pedro De Marchi; Renato de Castro Capuzzo; Ricardo Ribeiro Gama; Domingos Boldrini Junior; Carlos Roberto Santos; Gustavo Dix Junqueira Pinto; Josiane Mourão Dias; Heloisa Pelisser Canton; Raiany Carvalho; Lucas Augusto Radicchi; Soren Bentzen; Eduardo Zubizarreta; Andre Lopes Carvalho
Journal:  BMC Cancer       Date:  2018-10-23       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.